Abstract: Disclosed is a method for detecting an antigen-specific activated T cell comprising: acquiring first information on a particle size and second information on a T cell activation marker for a first measurement sample prepared by mixing in vitro a first specimen separated from a biological sample containing a T cell and an antigen-presenting cell and an antigen reagent containing a predetermined antigen, by measuring the first measurement sample with a flow cytometer; acquiring the first information and the second information for a second measurement sample prepared from a second specimen separated from the biological sample and not containing the antigen reagent, by measuring the second measurement sample with the flow cytometer; detecting a target particle in the first measurement sample based on the first information and the second information on the first measurement sample, and detecting a background particle in the second measurement sample based on the first information and the second information on the

Abstract: Disclosed is a method for assisting a determination of an efficacy of an immune checkpoint inhibitor, the method comprising: measuring a free protein marker in a liquid sample collected from a subject; and determining the efficacy of the immune checkpoint inhibitor in the subject based on a result of the measurement, wherein the free protein marker is at least one selected from free Cytotoxic T lymphocyte antigen-4 (CTLA-4), free Programmed cell death-1 (PD-1) and free Programmed cell death-ligand 1 (PD-L1).

Abstract: The present invention relates to a method for determining cancer, the method comprising the steps of: measuring free PD-L1 (Programmed cell death-ligand 1) and free PD-1 (Programmed cell death-1) as free protein markers in a liquid sample collected from a subject, and determining whether or not the liquid sample is a sample collected from a subject suffering from cancer, based on measurement results.

Abstract: The present invention relates to a marker allowing specific detection of human IL-17-producing helper T-cells (human Th17 cells), a method for specifically detecting human Th17 cells and a reagent for detecting human Th17 cells.

Abstract: An object is to provide a method for specific detection of human IL-17-producing helper T-cells (human Th17 cells). The method comprises: obtaining an expression level of the marker comprising a protein encoded by a gene represented by at least one selected from the group consisting of L1CAM, MCAM and PTPRM or a functionally equivalent variant or a fragment thereof, in a sample containing cells; and detecting human IL-17-producing helper T cells in the sample, based on the obtained expression level of the marker.

Abstract: An object is to provide a method for evaluating presence of rheumatoid arthritis by using a new biomarker set. The object is achieved by a method for evaluating presence of rheumatoid arthritis, in which the method includes the steps of: acquiring, from a biological specimen obtained from a subject, information regarding expression level of a first biomarker which is SLC16A4, and information regarding expression level of at least one second biomarker selected from the group consisting of SLCO2B1, PTPRM, SHB, and ATP9A; and evaluating presence of rheumatoid arthritis in the subject based on the information regarding expression levels of the acquired first and second biomarkers.

Abstract: The present invention relates to polynucleotide markers and protein markers for detecting human follicular helper T cells. The present invention also relates to methods for detecting human follicular helper T cells using the markers.

Abstract: The present invention relates to a marker allowing specific detection of human IL-17-producing helper T-cells (human Th17 cells), a method for specifically detecting human Th17 cells and a reagent for detecting human Th17 cells.

Abstract: The present invention relates to a marker allowing specific detection of human IL-17-producing helper T-cells (human Th17 cells), a method for specifically detecting human Th17 cells and a reagent for detecting human Th17 cells.

Abstract: Disclosed is at least one polynucleotide marker or protein marker which enables the specific detection of an IL-17-producing helper T cell (a Th17 cells). Also disclosed is a method for detecting a Th17 cell, which is characterized by comprising detecting the occurrence of the above-mentioned at least one marker.

Abstract: Disclosed is a polynucleotide marker or a protein marker for use in the specific detection of an IL-17-producing helper T-cell (a Th17 cell). Also disclosed is a method for detecting a Th17 cell, which is characterized by detecting the occurrence of the polynucleotide marker or the protein marker.